Clinical Trials · NCT07587710

A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function

Not Yet RecruitingPhase 1Amycretin (Investigational)
Phase
Phase 1
Recruitment status
Not Yet Recruiting
Sponsor
Novo Nordisk A/S
Enrollment
35
Start date
May 2026
Locations
2 sites, Slovakia
Primary endpoint
AUC0-∞: The area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose
View Amycretin compound reference